Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss

SJ Hume; S Hall; G Burns; S Vogrin; D Tassone; P Desmond; D Ratnam; MT Levy; R Sawhney; A Nicoll; Z Valaydon; SI Strasser; M Ngu; M Sinclair; C Meredith; GV Matthews; K Visvanathan; JA Holmes; AJ Thompson

Journal article

Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss

SJ Hume, S Hall, G Burns, S Vogrin, D Tassone, P Desmond, D Ratnam, MT Levy, R Sawhney, A Nicoll, Z Valaydon, SI Strasser, M Ngu, M Sinclair, C Meredith, GV Matthews, K Visvanathan, JA Holmes, AJ Thompson

Alimentary Pharmacology and Therapeutics | Wiley | Published : 2026

DOI: 10.1111/apt.70332

Download PDF

Abstract

Background and Aims: Discontinuing nucleos(t)ide analogues (NAs) may lead to functional cure (HBsAg loss) in selected patients with chronic hepatitis B (CHB). We evaluated the rates and predictors of HBsAg loss during long-term follow-up in a prospective cohort. Methods: This real-world extension study followed participants from a prospective trial of NA discontinuation. All patients had HBeAg-negative CHB without cirrhosis. Efficacy outcomes (including HBsAg loss and decline) and safety outcomes [including hepatitis flare and hepatocellular carcinoma (HCC)] were evaluated. Results: Amongst 97 participants (85% Asian), with a median follow-up of 7 years, the cumulative incidence of HBsAg los..

View full abstract